Loading patent…
AssigneeSantaris Pharma A/S
InventorsSigne M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
Estimating the term…
A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
1-43. (canceled)
A LNA nucleoside having the formula:
A gapmer oligomer having 10-15 nucleotide units, comprising central region of at least 4, 5, 6, 7 or 8 DNA nucleotides which is flanked both 5′ and 3′ by locked nucleotides having the formula:
A gapmer oligomer having 12-14 nucleotide units having a central region of at least 8 DNA nucleotides which is flanked both 5′ and 3′ by 1-3 locked nucleotides having the formula:
Dependencies are inferred from the claim text.